Two Sigma Investments’s IRulya Therapeutics Inc. Common Stock IRLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
– Sell
-356
Closed -$7.22K – 5349
2026
Q1
$7.22K Sell
356
-549
-61% -$110K ﹤0.01% 4537
2025
Q4
$606K Buy
905
+830
+1,107% +$418K ﹤0.01% 3205
2025
Q3
$24.6K Sell
75
-12
-14% -$4K ﹤0.01% 3587
2025
Q2
$28.7K Sell
87
-119
-58% -$27.2K ﹤0.01% 3101
2025
Q1
$54.7K Buy
206
+54
+36% +$16.5K ﹤0.01% 3035
2024
Q4
$56.7K Buy
+152
New +$45.7K ﹤0.01% 3031
2024
Q1
– Sell
-66
Closed -$13.8K – 3319
2023
Q4
$13.8K Sell
66
-32
-33% -$6.41K ﹤0.01% 3065
2023
Q3
$22K Sell
98
-250
-72% -$65.3K ﹤0.01% 2866
2023
Q2
$105K Sell
348
-287
-45% -$89.3K ﹤0.01% 2753
2023
Q1
$198K Sell
635
-1,701
-73% -$333K ﹤0.01% 2558
2022
Q4
$298K Sell
2,336
-152
-6% -$25.4K ﹤0.01% 2251
2022
Q3
$662K Sell
2,488
-64
-3% -$24.4K ﹤0.01% 1646
2022
Q2
$1.13M Buy
2,552
+171
+7% +$121K ﹤0.01% 1490
2022
Q1
$2.95M Sell
2,381
-606
-20% -$825K 0.01% 1173
2021
Q4
$7.54M Buy
2,987
+2,622
+718% +$16M 0.02% 952
2021
Q3
$6.7M Buy
365
+184
+102% +$2.93M 0.02% 1015
2021
Q2
$1.92M Sell
181
-7
-4% -$58.7K ﹤0.01% 1907
2021
Q1
$1.35M Buy
188
+86
+84% +$619K ﹤0.01% 2038
2020
Q4
$564K Buy
102
+39
+62% +$346K ﹤0.01% 2425
2020
Q3
$627K Buy
63
+9
+17% +$81.9K ﹤0.01% 2071
2020
Q2
$501K Buy
+54
New +$495K ﹤0.01% 1993

Other funds holding IRLA

Two Sigma Investments's IRLA Position: Q2 2026 in Review

Two Sigma Investments sold out of IRulya Therapeutics Inc. Common Stock (IRLA) in Q2 2026, closing a stake of 356 shares — an estimated $7.22K sold.

Two Sigma Investments first reported a position in IRLA in Q2 2020 and held it in 21 quarters. The position peaked at $7.54M in Q4 2021. 26 funds tracked by Wall St. Rank hold IRLA as of Q2 2026.

  • Two Sigma Investments reported no remaining IRulya Therapeutics Inc. Common Stock position as of Q2 2026 after selling out during the quarter.
  • Two Sigma Investments sold 356 IRulya Therapeutics Inc. Common Stock shares in Q2 2026, an estimated $7.22K.
  • Two Sigma Investments first reported a position in IRulya Therapeutics Inc. Common Stock in Q2 2020 and held it in 21 quarters.
  • Two Sigma Investments's IRulya Therapeutics Inc. Common Stock position peaked at $7.54M in Q4 2021.
  • 26 funds tracked by Wall St. Rank held IRulya Therapeutics Inc. Common Stock as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.